Literature DB >> 12475802

Roles for insulin-like growth factor I and transforming growth factor-beta in fibrotic lung disease.

Peter M Krein1, Brent W Winston.   

Abstract

Idiopathic pulmonary fibrosis (IPF) is a lung disease that is characterized by epithelial cell damage and areas of denuded basement membrane resulting in inflammation, fibroblast proliferation, excessive extracellular matrix (ECM) deposition, and remodeling of alveolar gas exchange units. The progressive loss of lung gas exchange units in patients with IPF leads to respiratory failure and eventually to death. While the etiology of this disease is unknown, for many years studies suggested that chronic inflammation was the underlying factor that caused fibroproliferation and structural alterations of the lung. Recent data show that fibroproliferation and fibrosis can occur independently of inflammation, suggesting that IPF is a disease caused by a mesenchymal, rather than an immune disorder. Mesenchymal growth factors, including transforming growth factor (TGF)-beta, insulin-like growth factor (IGF)-I, platelet-derived growth factor, connective tissue growth factor, fibroblast growth factors, and keratinocyte growth factors, as well as proinflammatory cytokines such as tumor necrosis factor-alpha and interleukin-1beta, have been shown to be exaggerated in several fibrotic lung disorders including IPF, ARDS, sarcoidosis, and bronchopulmonary dysplasia, as well as pulmonary manifestations of systemic diseases such as rheumatoid arthritis or progressive systemic sclerosis (scleroderma). We argue that inflammation is required to initiate growth factor production and repair of the damaged alveolar epithelial lining in fibrotic lung diseases and that exaggerated TGF-beta production may be responsible for the fibrotic response seen in diseases such as IPF. We recognize the potential role of several growth factors in the fibroproliferative process in the lung, and in this brief report we focus on the possible roles of the growth factors IGF-I and TGF-beta in cell migration, proliferation, and ECM synthesis in patients with IPF.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12475802     DOI: 10.1378/chest.122.6_suppl.289s

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  36 in total

1.  Macrophage-stimulating protein differently affects human alveolar macrophages from smoker and non-smoker patients: evaluation of respiratory burst, cytokine release and NF-kappaB pathway.

Authors:  Gabriele Gunella; Claudio Bardelli; Angela Amoruso; Ilario Viano; Piero Balbo; Sandra Brunelleschi
Journal:  Br J Pharmacol       Date:  2006-04-24       Impact factor: 8.739

2.  IGF1 and IGFBP3 in acute respiratory distress syndrome.

Authors:  Amy M Ahasic; Rihong Zhai; Li Su; Yang Zhao; Konstantinos N Aronis; B Taylor Thompson; Christos S Mantzoros; David C Christiani
Journal:  Eur J Endocrinol       Date:  2011-10-17       Impact factor: 6.664

Review 3.  Using mouse genomics to understand idiopathic interstitial fibrosis.

Authors:  David M Brass; John Tomfohr; Ivana V Yang; David A Schwartz
Journal:  Proc Am Thorac Soc       Date:  2007-01

Review 4.  Pathogenesis of Systemic Sclerosis.

Authors:  Debendra Pattanaik; Monica Brown; Bradley C Postlethwaite; Arnold E Postlethwaite
Journal:  Front Immunol       Date:  2015-06-08       Impact factor: 7.561

5.  Laminin α1 is a genetic modifier of TGF-β1-stimulated pulmonary fibrosis.

Authors:  Chang-Min Lee; Soo Jung Cho; Won-Kyung Cho; Jin Wook Park; Jae-Hyun Lee; Augustine M Choi; Ivan O Rosas; Ming Zheng; Gary Peltz; Chun Geun Lee; Jack A Elias
Journal:  JCI Insight       Date:  2018-09-20

Review 6.  Different effects of growth factors on proliferation and matrix production of normal and fibrotic human lung fibroblasts.

Authors:  M Hetzel; M Bachem; D Anders; G Trischler; M Faehling
Journal:  Lung       Date:  2005 Jul-Aug       Impact factor: 2.584

Review 7.  Insulin-like growth factor-I regulation of immune function: a potential therapeutic target in autoimmune diseases?

Authors:  Terry J Smith
Journal:  Pharmacol Rev       Date:  2010-04-14       Impact factor: 25.468

8.  CCR2 deficiency does not provide sustained improvement of muscular dystrophy in mdx5cv mice.

Authors:  Wanming Zhao; Xingyu Wang; Richard M Ransohoff; Lan Zhou
Journal:  FASEB J       Date:  2016-09-21       Impact factor: 5.191

9.  Metformin ameliorates bleomycin-induced pulmonary fibrosis in mice by suppressing IGF-1.

Authors:  Huijuan Xiao; Xiaoxi Huang; Shiyao Wang; Zheng Liu; Run Dong; Dingyun Song; Huaping Dai
Journal:  Am J Transl Res       Date:  2020-03-15       Impact factor: 4.060

10.  TGF-beta-induced interleukin-6 participates in transdifferentiation of human Tenon's fibroblasts to myofibroblasts.

Authors:  Gong Je Seong; Samin Hong; Sun-Ah Jung; Jung-Jin Lee; Eunhae Lim; Sung-Joo Kim; Joon H Lee
Journal:  Mol Vis       Date:  2009-10-21       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.